CORona Drug InTEractions database
SARS-CoV-2 Nucleocapsid Assembly Inhibitors: Repurposing Antiviral and Antimicrobial Drugs Targeting Nucleocapsid-RNA Interaction
Debica Mukherjee, UPASANA RAY
Abstract
SARS-CoV-2 pandemic has become a serious concern due to high transmission of this virus and unavailability of any definitive drugs yet in clinics. While novel antivirals are under investigation stage, scientists are also rigorously trying to use drug repurposing as an option to fight against this highly infectious novel coronavirus. Several drugs are under regular use for other diseases that are getting screened for their usability against SARS-CoV2. In this study we have targeted SARS-CoV-2 nucleocapsid assembly to shortlist FDA approved drugs that could be tested for inhibition of SARS-CoV-2 virus particles inside the host cell. We could shortlist seven antiviral and anti-microbial drugs. These showed good fit in docking studies inside the RNA binding cleft of the nucleocapsid protein. Also, these drugs have good lipophilic properties suggesting that they would enter the host cells. We propose that these shortlisted drugs could potentially compete out binding of viral RNA to nucleocapsid and thus inhibit successful virus assembly leading to poor virus progeny levels.
Source: ChemRxiv
Related molecules
Related interactions
| Target | Target affiliation | Drug | Type | Result |
|---|---|---|---|---|
| Target | Target affiliation | Drug | Type | Result |
| Name | Synonyms | Genes | Origin |
|---|---|---|---|
| Name | Synonyms | Genes | Origin |
| Name | Synonyms | PubChem | DrugBank | RCSB PDB | ATC |
|---|---|---|---|---|---|
| Name | Synonyms | PubChem | DrugBank | RCSB PDB | ATC |
| Title | Authors | DOI | Source | Article type | Date |
|---|---|---|---|---|---|
| Title | Authors | DOI | Source | Article type | Date |
| Title | Status | Phases | Start Date | Prim. Comp. Date | Comp. Date | First Post. Date |
|---|---|---|---|---|---|---|
| Title | Status | Phases | Start Date | Prim. Comp. Date | Comp. Date | First Post. Date |
CORDITE (CORona Drug InTEractions database) collects and aggregates data from PubMed, MedRxiv, BioRxiv, ChemRxiv and PMC for SARS-CoV-2. Its main focus is set on drug interactions either addressing viral proteins or human proteins that could be used to treat COVID. It collects and provides up-to-date information on computational predictions, in vitro, as well as in vivo study data.
The information provided is for research only and we cannot guarantee the correctness of the data.
Please contact dominik.heider@uni-muenster.de for further information.
Programmable access
There is an open API for access programmatically to the database. The API will print a JSON output:
- Interactions
https://cordite-api.uni-muenster.de/api.php?action=list&table=interaction
- Targets
https://cordite-api.uni-muenster.de/api.php?action=list&table=target
- Drugs
https://cordite-api.uni-muenster.de/api.php?action=list&table=drug
- Publications
https://cordite-api.uni-muenster.de/api.php?action=list&table=publication
- Clinical trials
https://cordite-api.uni-muenster.de/api.php?action=list&table=clinical_trial